Treatment-Resistant Depression&nbsp;
&nbsp;
Treatment-resistant Depression (TRD) typically refers to inadequate response to at least one antidepressant trial of adequate doses and duration. Treatment-resistant Depression is a relatively common occurrence in clinical practice, with up to 50&ndash;60% of the patients not achieving adequate response following antidepressant treatment.
&nbsp;
Treatment-Resistant Depression Epidemiology Segmentation in the 7MM&nbsp;
&nbsp;
<ul>
<li class="ql-align-justify">Total Diagnosed Prevalent Cases Treatment-Resistant Depression</li>
<li class="ql-align-justify">Age-Specific Cases of Treatment-Resistant Depression</li>
<li class="ql-align-justify">Gender-specific Cases of Treatment-Resistant Depression</li>
</ul>
&nbsp;
Treatment-Resistant Depression Epidemiological Insights Observed in the 7MM (2021)
&nbsp;
<ul>
<li class="ql-align-justify">The total prevalent cases of Treatment-Resistant Depression in the 7MM were estimated to be 5.8 million.</li>
<li class="ql-align-justify">The total prevalent cases of Treatment-Resistant Depression in the US were estimated to be 3.9 million.</li>
<li class="ql-align-justify">The total prevalent cases of Treatment-Resistant Depression in Germany was found to be&nbsp;558k and in Italy, they were found to be 127k in the year 2021.</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/treatment-resistant-depression-market" target="_blank" rel="noopener noreferrer">Treatment-Resistant Depression Market Insight</a>
&nbsp;
The market size of Treatment-Resistant Depression in the 7MM was found to be USD 2,450 million in 2021.
 &nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight" target="_blank" rel="noopener noreferrer">Treatment-Resistant Depression Emerging Therapies</a>
&nbsp;
The emerging drugs in the Treatment-Resistant Depression market are
&nbsp;
<ul>
<li class="ql-align-justify">AXS-05</li>
<li class="ql-align-justify">VRAYLAR</li>
<li class="ql-align-justify">Esketamine DPI</li>
<li class="ql-align-justify">REL-1017</li>
<li class="ql-align-justify">COMP360</li>
<li class="ql-align-justify">MIJ821</li>
<li class="ql-align-justify">Liafensine</li>
<li class="ql-align-justify">MK-1942</li>
<li class="ql-align-justify">NV5138</li>
<li class="ql-align-justify">TS161</li>
<li class="ql-align-justify">AV-101, and many others</li>
</ul>
&nbsp;
Treatment-Resistant Depression Key Players&nbsp;
&nbsp;
The key players working in the Treatment-Resistant Depression market are
&nbsp;
<ul>
<li class="ql-align-justify">Axsome Therapeutics</li>
<li class="ql-align-justify">AbbVie</li>
<li class="ql-align-justify">Celon Pharma</li>
<li class="ql-align-justify">Relmada Therapeutics</li>
<li class="ql-align-justify">COMPASS Pathways</li>
<li class="ql-align-justify">Novartis</li>
<li class="ql-align-justify">Denovo Biopharma</li>
<li class="ql-align-justify">Merck Sharp and Dohme Corp</li>
<li class="ql-align-justify">Navitor Pharmaceuticals, Inc.</li>
<li class="ql-align-justify">Supernus Pharmaceuticals, Inc.</li>
<li class="ql-align-justify">Taisho Pharmaceutical Co., Ltd</li>
<li class="ql-align-justify">VistaGen Therapeutics, and several others</li>
</ul>

Treatment-Resistant Depression Market

 Treatment-Resistant Depression Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape.